Trial Profile
Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease [EXTENSION OF 700245239]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Denufosol (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms DEFY
- Sponsors Merck Sharp & Dohme Corp.
- 30 May 2014 New trial record